Pulmonary Arterial Hypertension Associated with Portal Hypertension and HIV Infection: Comparative Characteristics and Prognostic Predictors.
Child–Turcotte–Pugh (CTP)
highly active antiretroviral therapy (HAART)
human immunodeficiency virus (HIV)
model for end-stage liver disease-Na (MELD-Na)
portal hypertension
pulmonary arterial hypertension
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
12 May 2023
12 May 2023
Historique:
received:
13
04
2023
revised:
06
05
2023
accepted:
09
05
2023
medline:
27
5
2023
pubmed:
27
5
2023
entrez:
27
5
2023
Statut:
epublish
Résumé
Pulmonary arterial hypertension (PAH) may complicate both portal hypertension (Po-PAH) and HIV infection (HIV-PAH). These two conditions, however, frequently coexist in the same patient (HIV/Po-PAH). We evaluated clinical, functional, hemodynamic characteristics and prognostic parameters of these three groups of patients. We included patients with Po-PAH, HIV-PAH and HIV/Po-PAH referred to a single center. We compared clinical, functional and hemodynamic parameters, severity of liver disease [Child-Turcotte-Pugh (CTP) and Model for End-stage Liver Disease-Na (MELD-Na) scores], CD4 count and highly active antiretroviral therapy (HAART) administration. Prognostic variables were identified through Cox-regression analysis. Patients with Po-PAH ( Patients with HIV/Po-PAH are younger and have a better exercise capacity than patients with Po-PAH, have a better exercise capacity and hemodynamic profile compared to patients with HIV-PAH, and their prognosis seems to be related to the hepatic disease rather than to HIV infection. The prognosis of patients with Po-PAH and HIV-PAH seems to be related to the underlying disease.
Sections du résumé
BACKGROUND
BACKGROUND
Pulmonary arterial hypertension (PAH) may complicate both portal hypertension (Po-PAH) and HIV infection (HIV-PAH). These two conditions, however, frequently coexist in the same patient (HIV/Po-PAH). We evaluated clinical, functional, hemodynamic characteristics and prognostic parameters of these three groups of patients.
METHODS
METHODS
We included patients with Po-PAH, HIV-PAH and HIV/Po-PAH referred to a single center. We compared clinical, functional and hemodynamic parameters, severity of liver disease [Child-Turcotte-Pugh (CTP) and Model for End-stage Liver Disease-Na (MELD-Na) scores], CD4 count and highly active antiretroviral therapy (HAART) administration. Prognostic variables were identified through Cox-regression analysis.
RESULTS
RESULTS
Patients with Po-PAH (
CONCLUSIONS
CONCLUSIONS
Patients with HIV/Po-PAH are younger and have a better exercise capacity than patients with Po-PAH, have a better exercise capacity and hemodynamic profile compared to patients with HIV-PAH, and their prognosis seems to be related to the hepatic disease rather than to HIV infection. The prognosis of patients with Po-PAH and HIV-PAH seems to be related to the underlying disease.
Identifiants
pubmed: 37240531
pii: jcm12103425
doi: 10.3390/jcm12103425
pmc: PMC10219491
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
J Hepatol. 2020 Jul;73(1):130-139
pubmed: 32145258
Liver Transpl. 2000 Jul;6(4):443-50
pubmed: 10915166
Chest. 1999 Jun;115(6):1748-9
pubmed: 10378581
Eur Respir J. 2015 Aug;46(2):414-21
pubmed: 26022952
Z Gastroenterol. 2011 Sep;49(9):1258-62
pubmed: 21887662
Eur Respir J. 2017 Aug 3;50(2):
pubmed: 28775047
Transplantation. 1997 Feb 27;63(4):604-6
pubmed: 9047158
Am J Respir Crit Care Med. 1997 Mar;155(3):990-5
pubmed: 9117037
Chest. 2012 Apr;141(4):906-915
pubmed: 21778257
AIDS. 2010 Jan 2;24(1):67-75
pubmed: 19770696
Transpl Int. 2009 May;22(5):554-61
pubmed: 19175541
Chest. 2019 Aug;156(2):323-337
pubmed: 30772387
Am J Respir Crit Care Med. 2022 May 1;205(9):1121-1124
pubmed: 35180043
Eur Respir J. 2017 Aug 3;50(2):
pubmed: 28775050
BMC Gastroenterol. 2020 Apr 6;20(1):91
pubmed: 32252653
J Viral Hepat. 2008 Mar;15(3):165-72
pubmed: 18233989
Eur J Gastroenterol Hepatol. 2022 Apr 1;34(4):449-456
pubmed: 34907982
Eur Respir J. 2006 Sep;28(3):563-7
pubmed: 16807265
Chest. 2021 Jan;159(1):328-336
pubmed: 32798521
J Infect. 2000 May;40(3):282-4
pubmed: 10908024
Clin Infect Dis. 2004 Apr 15;38(8):1178-85
pubmed: 15095226
Transplant Direct. 2021 Jun 08;7(7):e710
pubmed: 34124346
AIDS Res Ther. 2015 Nov 11;12:36
pubmed: 26566389
Medicine (Baltimore). 2022 Apr 1;101(13):e29162
pubmed: 35421069
Am J Respir Crit Care Med. 2002 Jul 1;166(1):111-7
pubmed: 12091180
Lancet Respir Med. 2019 Jul;7(7):594-604
pubmed: 31178422
JAMA. 2013 Nov 27;310(20):2191-4
pubmed: 24141714
N Engl J Med. 2013 Jul 25;369(4):330-40
pubmed: 23883378
J Hepatol. 1998 Feb;28(2):337-42
pubmed: 9514547
Eur Respir J. 2013 Jan;41(1):96-103
pubmed: 22653773
J Indian Med Assoc. 2013 Dec;111(12):845-6, 849
pubmed: 25154159
Am J Transplant. 2008 Nov;8(11):2445-53
pubmed: 18782292
Eur Respir J. 2007 Dec;30(6):1096-102
pubmed: 17652314
AIDS. 2012 Jul 17;26(11):1387-92
pubmed: 22526521
Liver Transpl. 2021 Dec;27(12):1811-1823
pubmed: 33964116
Eur Respir J. 2022 Aug 4;60(2):
pubmed: 35680147
Open Heart. 2021 Oct;8(2):
pubmed: 34667092
Br J Radiol. 2021 Aug 1;94(1124):20210061
pubmed: 34106779
Eur Heart J. 2022 Oct 11;43(38):3618-3731
pubmed: 36017548
J Intern Med. 2022 Jul;292(1):116-126
pubmed: 35184348